Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives.

Expert review of molecular diagnostics - 1 Nov 2007

Kim Tae-You, Han Sae-Won, Bang Yung-Jue

Abstract excerpt

EGF receptor (EGFR) activation has an important role in various steps of carcinogenesis and progression of non-small-cell lung cancer (NSCLC), implying that EGFR is a potential target for cancer therapy. Therefore, targeted treatments aimed at EGFR have been developed, of which tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib have shown activity in NSCLC. The unexpected findings of a lack of association...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Gene Dosage

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 18020911
DOI: 10.1586/14737159.7.6.821

Genes

EGFR
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives.PMID 18020911Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues.Semantic proximity Read ↗

Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?Semantic proximity Read ↗

Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors.Semantic proximity Read ↗

Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer.Semantic proximity Read ↗

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.Semantic proximity Read ↗

Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.Semantic proximity Read ↗

Review. EGFR mutations in non-small cell lung cancer--clinical implications.Semantic proximity Read ↗

[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].Semantic proximity Read ↗

Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.Semantic proximity Read ↗

Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.